News Novo's semaglutide outperforms Lilly GLP-1 rival If approved semaglutide could become set the standard for GLP-1 therapy
News RA pill setback spoils Lilly’s growth story Eli Lilly has posted a strong 8% increase in sales for the second quarter, led by grow
News Surge of Alzheimer's drugs in pipeline gives hope of progres... Authors "optimistic" despite issues with front runners from AB Science and Otsuka
News J&J's psoriasis drug faces crowded market after US approval J&J taking on next gen drugs from Novartis, Eli Lilly, and Valeant.
News FDA fast-tracks Lilly/Pfizer pain drug amid opioid crisis Companies hope tanezumab offers alternative to opioids
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.